Dr. Michael Offin
Claim this profileMemorial Sloan Kettering Cancer Center
Studies Mesothelioma
Studies Lung Cancer
5 reported clinical trials
12 drugs studied
Area of expertise
1Mesothelioma
systemic
unresectable
2Lung Cancer
Stage IV
BRAF positive
NRAS positive
Affiliated Hospitals
Clinical Trials Michael Offin is currently running
Sacituzumab Govitecan
for Mesothelioma
Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.
Recruiting1 award Phase 24 criteria
BDTX-4933
for Cancer
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and/or CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. However, the study may also proceed directly to the expansion phase. The study population for the Dose Expansion part of the study comprises adults with advanced/metastatic NSCLC with KRAS and/or BRAF mutations, and with Pancreatic Ductal AdenoCarcinoma (PDAC), ColoRectal Cancer (CRC), and Biliary Tract Cancer (BTC) with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations and alterations. All patients will self-administer S241656 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.
Recruiting1 award Phase 1 & 2
More about Michael Offin
Clinical Trial Related8 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Michael Offin has experience with
- Sacituzumab Govitecan
- Cisplatin Or Carboplatin
- Nivolumab
- Pemetrexed
- Surgery
- LTT462
Breakdown of trials Michael Offin has run
Mesothelioma
Lung Cancer
Malignant Pleural Mesothelioma
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Offin specialize in?
Michael Offin focuses on Mesothelioma and Lung Cancer. In particular, much of their work with Mesothelioma has involved systemic patients, or patients who are unresectable.
Is Michael Offin currently recruiting for clinical trials?
Yes, Michael Offin is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Michael Offin has studied deeply?
Yes, Michael Offin has studied treatments such as Sacituzumab Govitecan, Cisplatin or Carboplatin, Nivolumab.
What is the best way to schedule an appointment with Michael Offin?
Apply for one of the trials that Michael Offin is conducting.
What is the office address of Michael Offin?
The office of Michael Offin is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.